Takara Bio licenses TCR and CART therapy products out to Otsuka Pharma

Takara Bio has announced on April 9 that two gene therapeutic agents for T cell therapy, NY-ESO-1 · siTCRTM, and NY-ESO- (TBI-1301, TBI-1301-A), and a CART cell product, CD 19 · CAR (TBI-1501), a chimeric antigen receptor transgenic T cell (CART) therapy targeting CD 19, jointly developed by both companies, will be exclusively sold by Otsuka Pharmaceutical.

Source: Takara Bio news release, April 9, 2018

Request a quote for deeper information from

© 2018 Window to Japan - Bio 4 Business - Imprint